LataMed AI's Mobile Healthcare App Nears Public Release, Targeting Latin America's Smartphone-Dependent Market

LataMed AI Corp. (OTC: LMED) announced that development of its mobile healthcare application has entered its final stage, with the company completing testing, optimization, and deployment preparations ahead of planned availability through the Apple App Store and Google Play. Management expects the application to be submitted for distribution and, subject to platform review and technical requirements, become available in the coming weeks.

This transition from development to public availability is significant for the company's digital healthcare ecosystem, as the app is designed to be a primary mobile access point for users to interact with supported healthcare services and digital tools. The company's development team is focused on final technical testing, interface optimization, and platform compatibility to ensure a smooth launch.

The strategic importance of mobile accessibility is particularly pronounced in Latin America, where smartphones are a primary means of accessing digital services for many individuals. By launching on both major mobile marketplaces, LataMed AI aims to provide a direct and accessible way for users to engage with its healthcare ecosystem, while establishing scalable infrastructure for future expansion.

The application is expected to support the company's longer-term strategy of connecting patients, healthcare professionals, pharmacies, insurers, payment providers, and wellness organizations in a more integrated digital healthcare environment. LataMed AI continues to develop its artificial intelligence-supported technologies, including CardioAI, PulmoAI, and NeuroAI, as part of its broader strategy. The mobile infrastructure is intended to serve as an additional pathway for users and healthcare professionals to interact with these AI tools, subject to continued development and regulatory requirements.

Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI, said, "Our mobile application is now moving from development toward deployment, and we believe we are approaching an important milestone for LataMed AI. Our team is completing the final stages of testing and preparation, and we currently expect the application to become available through the Apple App Store and Google Play in the coming weeks, subject to the applicable platform review processes."

Dr. Levy added, "Mobile availability is important because it provides a direct connection between users and the digital healthcare ecosystem we are building. Our objective is to create a platform that is practical, accessible, and capable of expanding as we continue introducing additional healthcare services and artificial intelligence-supported tools."

The anticipated release of the mobile application represents another step in moving LataMed AI's technology from development into user-facing digital healthcare infrastructure. Following the initial release, the company intends to evaluate additional functionality, platform integrations, and user-facing tools for future versions. The company expects to provide updates regarding submission, availability, and functionality as milestones are completed.

For more information, visit https://latamed.ai or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.